The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options

International Journal of Antimicrobial Agents

Volumn 46, Issue , 2015, Pages S47-S50

  Postma, Nynke ^a   Kiers, Dorien ^a   Pickkers, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic associated diarrhoea; Clostridium difficile; Colitis; Diagnosis; Therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTITOXIN; BACTERIAL TOXIN; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; RAMOPLANIN; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASYMPTOMATIC INFECTION; BACTERIAL COLONIZATION; BACTERIUM CARRIER; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLITIS; COLON RESECTION; COLONOSCOPY; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG WITHDRAWAL; ENDOSCOPY; FECES ANALYSIS; FULMINANT COLITIS; HISTOPATHOLOGY; HUMAN; ILEOSTOMY; INFECTION CONTROL; MULTIDRUG RESISTANCE; MULTIPLE ORGAN FAILURE; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SYMPTOM; TREATMENT INDICATION; BIOLOGICAL THERAPY; CASE MANAGEMENT; CLOSTRIDIUM INFECTIONS; DRUG THERAPY; ISOLATION AND PURIFICATION; PATHOLOGY; PROCEDURES; SURGERY;

BIOLOGICAL THERAPY; CASE MANAGEMENT; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; DIAGNOSTIC TESTS, ROUTINE; DRUG THERAPY; HUMANS; SURGICAL PROCEDURES, OPERATIVE;

EID: 84949530056     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.11.001     Document Type: Article

References (50)

1. J.G. Bartlett, T.W. Chang, M. Gurwith, S.L. Gorbach, and A.B. Onderdonk Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia N Engl J Med 298 1978 531 534
2. A. Elixhauser, and M. Jhung Clostridium difficile-associated disease in US hospitals, 1993-2005: statistical brief #50. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs 2006-2008, April US Agency for Health Care Policy and Research Rockville, MD
3. K.R. Reveles, G.C. Lee, N.K. Boyd, and C.R. Frei The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010 Am J Infect Control 42 2014 1028 1032
4. J. Pépin, L. Valiquette, S. Gagnon, S. Routhier, and I. Brazeau Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027 Am J Gastroenterol 102 2007 2781 2788
5. S. Johnson, M.H. Samore, K.A. Farrow, G.E. Killgore, F.C. Tenover, D. Lyras, and et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals N Engl J Med 341 1999 1645 1651
6. J. Pépin, N. Saheb, M.A. Coulombe, M.E. Alary, M.P. Corriveau, S. Authier, and et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec Clin Infect Dis 41 2005 1254 1260
7. M.J. Gurwith, H.R. Rabin, and K. Love Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study J Infect Dis 135 Suppl 1977 S104 S110
8. A. Deshpande, V. Pasupuleti, P. Thota, C. Pant, D.D. Rolston, T.J. Sferra, and et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis J Antimicrob Chemother 68 2013 1951 1961
9. M.H. Wilcox, L. Mooney, R. Bendall, C.D. Settle, and W.N. Fawley A case-control study of community-associated Clostridium difficile infection J Antimicrob Chemother 62 2008 388 396
10. S. Khanna, D.S. Pardi, S.L. Aronson, P.P. Kammer, R. Orenstein, J.L. St Sauver, and et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study Am J Gastroenterol 107 2012 89 95 Erratum in: Am J Gastroenterol 2012;107:150
11. E. Zimlichman, D. Henderson, O. Tamir, C. Franz, P. Song, C.K. Yamin, and et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system JAMA Intern Med 173 2013 2039 2046
12. C.P. Kelly, and J.T. LaMont Clostridium difficile-more difficult than ever N Engl J Med 359 2008 1932 1940
13. N. Bagdasarian, K. Rao, and P.N. Malani Diagnosis and treatment of Clostridium difficile in adults: a systematic review JAMA 313 2015 398 408
14. C. Pothoulakis Effects of Clostridium difficile toxins on epithelial cell barrier Ann N Y Acad Sci 915 2000 347 356
15. M.J. Hopkins, and G.T. Macfarlane Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection J Med Microbiol 51 2002 448 454
16. F. Alasmari, S. Seile, T. Hink, C. Burnham, and E. Dubberke Prevalence and risk factors for asymptomatic Clostridium difficile carriage Clin Infect Dis 59 2014 216 222
17. L. Kyne, M. Warny, A. Qamar, and C.P. Kelly Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A N Engl J Med 34 2000 390 397
18. L.V. McFarland, M.E. Mulligan, R.Y. Kwok, and W.E. Stamm Nosocomial acquisition of Clostridium difficile infection N Engl J Med 320 1989 204 210
19. M.M. Riggs, A.K. Sethi, T.F. Zabarsky, E.C. Eckstein, R.L. Jump, and C.J. Donskey Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents Clin Infect Dis 45 2007 992 998
20. J.K. Shim, S. Johnson, M.H. Samore, D.Z. Blizz, and D.N. Gerding Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea Lancet 351 1998 633 636
21. A. Wanahita, E.A. Goldsmith, and D.M. Musher Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile Clin Infect Dis 34 2002 1585 1592
22. F.J. Tedesco Pseudomembranous colitis: pathogenesis and therapy Med Clin North Am 66 1982 655 664
23. S.B. Debast, M.P. Bauer, and E.J. Kuijper European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection Clin Microbiol Infect 20 Suppl 2 2014 1 26
24. S. Johnson, T.J. Louie, D.N. Gerding, O.A. Cornely, S. Chasan-Taber, D. Fitts, and et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials Clin Infect Dis 59 2014 345 354
25. L.C. McDonald, B. Coignard, E. Dubberke, X. Song, T. Horan, P.K. Kutty, and et al. Recommendations for surveillance of Clostridium difficile-associated disease Infect Control Hosp Epidemiol 28 2007 140 145
26. L.V. McFarland, C.M. Surawicz, M. Rubin, R. Fekety, G.W. Elmer, and R.N. Greenberg Recurrent Clostridium difficile disease: epidemiology and clinical characteristics Infect Control Hosp Epidemiol 20 1999 43 50
27. R. Fekety, L.V. McFarland, C.M. Surawicz, R.N. Greenberg, G.W. Elmer, and M.E. Mulligan Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial Clin Infect Dis 24 1997 324 333
28. L.V. McFarland, G.W. Elmer, and C.M. Surawicz Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease Am J Gastroenterol 97 2002 1769 1775
29. D.A. Leffler, and J.T. Lamont Treatment of Clostridium difficile-associated disease Gastroenterology 136 2009 1899 1912
30. M.Y. Hu, K. Katchar, L. Kyne, S. Maroo, S. Tummala, V. Dreisbach, and et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection Gastroenterology 136 2009 1206 1214
31. O.A. Cornely, M.A. Miller, T.J. Louie, D.W. Crook, and S.L. Gorbach Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin Clin Infect Dis 55 Suppl 2 2012 S154 S161
32. F. Lamontagne, A.C. Labbé, O. Haeck, O. Lesur, M. Lalancette, C. Patino, and et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain Ann Surg 245 2007 267 272
33. J. Pépin, L. Valiquette, S. Gagnon, S. Routhier, and I. Brazeau Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027 Am J Gastroenterol 102 2007 2781 2788
34. S.H. Cohen, D.N. Gerding, S. Johnson, C.P. Kelly, V.G. Loo, L.C. McDonald, and et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) Infect Control Hosp Epidemiol 31 2010 431 455
35. T.J. Louie, M.A. Miller, K.M. Mullane, K. Weiss, A. Lentnek, Y. Golan, and et al. Fidaxomicin versus vancomycin for Clostridium difficile infection N Engl J Med 364 2011 422 431
36. O.A. Cornely, D.W. Crook, R. Esposito, A. Poirier, M.S. Somero, K. Weiss, and et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial Lancet Infect Dis 12 2012 281 289
37. A. Apisarnthanarak, B. Razavi, and L.M. Mundy Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature Clin Infect Dis 35 2002 690 696
38. R.M. Dallal, B.G. Harbrecht, A.J. Boujoukas, C.A. Sirio, L.M. Farkas, K.K. Lee, and et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications Ann Surg 235 2002 363 372
39. M.D. Neal, J.C. Alverdy, D.E. Hall, R.L. Simmons, and B.S. Zuckerbraun Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease Ann Surg 254 2011 423 427
40. D.A. Leffler, and J.T. Lamont Clostridium difficile infection N Engl J Med 373 2015 287 288
41. Z. Kassam, C.H. Lee, Y. Yuan, and R.H. Hunt Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis Am J Gastroenterol 108 2013 500 508
42. E. van Nood, A. Vrieze, M. Nieuwdorp, S. Fuentes, E.G. Zoetendal, W.M. de Vos, and et al. Duodenal infusion of donor feces for recurrent Clostridium difficile N Engl J Med 368 2013 407 415
43. H. Zainah, M. Hassan, L. Shiekh-Sroujieh, S. Hassan, G. Alangaden, and M. Ramesh Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection Dig Dis Sci 60 2015 181 185
44. C.R. Kelly, C. Ihunnah, M. Fischer, A. Khoruts, C. Surawicz, A. Afzali, and et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immuno-compromised patients Am J Gastroenterol 109 2014 1065 1071
45. N.S. Taylor, and J.G. Bartlett Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins J Infect Dis 141 1980 92 97
46. G.A. Mogg, Y. Arabi, D. Youngs, M. Johnson, S. Bentley, D.W. Burdon, and et al. Therapeutic trials of antibiotic associated colitis Scand J Infect Dis Suppl Suppl 22 1980 41 45
47. E.W. Kreutzer, and F.D. Milligan Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin Johns Hopkins Med J 143 1978 67 72
48. F.J. Tedesco Treatment of recurrent antibiotic-associated pseudomembranous colitis Am J Gastroenterol 77 1982 220 221
49. P. Juang, S.J. Skledar, N.K. Zgheib, D.L. Paterson, E.N. Vergis, W.D. Shannon, and et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea Am J Infect Control 35 2007 131 137
50. R.R. Roberts, B. Hota, I. Ahmad, R.D.2nd Scott, S.D. Foster, F. Abbasi, and et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship Clin Infect Dis 49 2009 1175 1184